
(Healthday News) — The U.S. Food and Drug Administration’s controversial approval of the Alzheimer’s drug Aduhelm should be investigated by the Office of Inspector General (OIG), FDA Acting Commissioner Dr. Janet Woodcock has said. The FDA approved Aduhelm even though an advisory panel of outside experts said there wasn’t enough proof that the drug actually… read on > read on >